Puma Biotechnology Stock Declines More Than 9% in a Month: Here's Why [Yahoo! Finance]
Puma Biotechnology Inc (PBYI)
Last puma biotechnology inc earnings: 2/20 04:07 pm
Check Earnings Report
US:NYSE Investor Relations:
pumabiotechnology.com/ir.html
Company Research
Source: Yahoo! Finance
Shares of Puma Biotechnology PBYI have tanked 9.6% in the past month, reflecting the growing investor concern regarding the company's soft 2026 revenue outlook. The company's sole marketed product, Nerlynx (neratinib), is approved for treating early-stage HER2-positive breast cancer in patients previously treated with Roche 's RHHBY Herceptin-based adjuvant therapy. Nerlynx is also approved in combination with Xeloda (capecitabine) for treating advanced or metastatic HER2-positive breast cancer patients who have received two or more prior anti-HER2-based regimens in the metastatic setting. Nerlynx sales currently comprise the majority of PBYI's top line. Sales of the drug increased 4.6% year over year to $204.1 million in 2025. Despite the increasing sales for Nerlynx, Puma Biotechnology issued a weaker-than-expected 2026 financial outlook last month. This can be attributed to the primary reason for the stock's decline in the past month. PBYI's 2026 Outlook Muted & Pipeline U
Show less
Read more
Impact Snapshot
Event Time:
PBYI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PBYI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PBYI alerts
High impacting Puma Biotechnology Inc news events
Weekly update
A roundup of the hottest topics
PBYI
News
- Puma Biotechnology (PBYI) was upgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=PBYI&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> from "hold"MarketBeat
- Puma Biotechnology Q4 Earnings Call Highlights [Yahoo! Finance]Yahoo! Finance
- Puma Biotechnology, Inc. (PBYI) Q4 2025 Earnings Call Transcript [Seeking Alpha]Seeking Alpha
- Puma Biotech: Q4 Earnings Snapshot [Yahoo! Finance]Yahoo! Finance
- Puma Biotechnology Reports Fourth Quarter and Full Year 2025 Financial ResultsBusiness Wire
PBYI
Earnings
- 2/26/26 - Beat
PBYI
Sec Filings
- 2/26/26 - Form 10-K
- 2/26/26 - Form 8-K
- 2/20/26 - Form 4
- PBYI's page on the SEC website